[0-49]: decrease dose by 50% (e.g. 10mg q12h or 20mg qhs) or extend
interval to q36-48h (to limit potential CNS adverse effects). Dosage Adjustments for Patients with
Moderate or Severe Renal Insufficiency
In adult patients with moderate (creatinine clearance <50 mL/min) or
severe (creatinine clearance <10 mL/min) renal insufficiency, the
elimination half-life of famotidine is increased. For patients with
severe renal insufficiency, it may exceed 20 hours, reaching
approximately 24 hours in anuric patients. Since CNS adverse effects
have been reported in patients with moderate and severe renal
insufficiency, to avoid excess accumulation of the drug in patients with
moderate or severe renal insufficiency, the dose of famotidine injection
may be reduced to half the dose, or the dosing interval may be prolonged
to 36 to 48 hours as indicated by the patient’s clinical response.
Based on the comparison of pharmacokinetic parameters for famotidine in
adults and pediatric patients, dosage adjustment in pediatric patients
with moderate or severe renal insufficiency should be considered.
Decrease dose by 50% (e.g. 10mg q12h or 20mg qhs) or extend interval
to q36-48h. Give dosage after dialysis on dialysis days.
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read